GlmU is a bifunctional enzyme with two distinct active sites:
C-terminal acetyltransferase domain: Transfers an acetyl group from acetyl-CoA to glucosamine-1-phosphate (GlcN-1-P), forming GlcNAc-1-P .
N-terminal uridyltransferase domain: Catalyzes the transfer of UMP from UTP to GlcNAc-1-P, generating UDP-GlcNAc .
Structural studies in related species (e.g., E. coli, Mycobacterium tuberculosis) reveal that GlmU forms a trimeric structure, with acetyltransferase active sites formed at the junction of adjacent subunits . The enzyme’s substrate specificity for UTP over ATP is critical for its role in cell wall biosynthesis .
GlmU is a validated antimicrobial target due to its essential role in bacterial viability and absence in humans . Inhibitors targeting its acetyltransferase domain (e.g., arylsulfonamides) or uridyltransferase domain (e.g., aminopiperidine derivatives) have shown promise in disrupting biofilm formation and bacterial growth .
Reconstitution: Dissolve lyophilized protein in deionized water (0.1–1.0 mg/mL) with 50% glycerol for stability .
Activity Assays: Monitor UDP-GlcNAc production via HPLC or enzymatic coupled assays .
Crystallization: Requires substrate-bound conditions (e.g., GlcN-1-P and UTP) for active-site visualization .
Further studies could explore:
KEGG: ppr:PBPRA3601
STRING: 298386.PBPRA3601